MAV+ Nigeria

Last updated: September 2025

Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+) is a comprehensive support package tackling barriers to manufacturing and access to health products and technologies in Africa. MAV+ is tightly aligned with African strategies and is supported by a broad and inclusive consortium of European actors.

Nigeria is well-positioned to be a regional and continental hub for vaccine and medicines manufacturing thanks to its active pharmaceutical industry and its achievement of WHO Maturity Level 3 in 2022. MAV+ supports Nigeria in increasing its regional impact by focusing on skills development, R&D, industrial development, resilient supply chains and digitalisation, regulatory strengthening and the ecosystem as a whole.

Key MAV+ collaborations and activities

Support to the development of the National Plan for Vaccine Research and Development and Local Production 2024-2034

Team Europe supported the development of the National Plan for Vaccine Research and Development and Local Production 2024-2034 by funding technical assistance to the National Institute for Pharmaceutical Research and Development (NIPRD) under the Federal Ministry of Health and Social Welfare.

> **Nigeria**
> **€30.37 million**
> **4 projects***
> *excludes multi-country projects

The Special Measure 2023 for Nigeria will further support NIPRD in implementing some aspects of the National Plan by strengthening local manufacturing capacity for medicines, vaccines and health technologies. Ongoing technical assistance will also support grant management, foster private sector engagement and ensure alignment with Nigeria's national roadmap and priorities.

Investing in local production of pharmaceutical ingredients

Team Europe has focused its efforts on Nigeria's thriving pharmaceutical industry, which includes more than 115 registered manufacturers. To cover supply gaps, EIB provided a €13.85 million loan to Emzor to support the expansion of its facilities to produce several active pharmaceutical ingredients, including those used in malaria treatments.

Additionally, as part of a multi-country project, Nigeria is enhancing its capacity to produce vaccines and essential medicines by seeking technology transfer partnerships within the private sector, developing regional marketing strategies for vaccines and building North-South technology transfer arrangements for critical medicines.

Enhancing Nigeria's pharmaceuticals ecosystem and market efficiency

Team Europe will also reinforce critical ecosystem components—including regulatory functions and supply chain operations—while supporting market-shaping efforts through Special Measure 2023. Key actions include capacity-building; digitalizing Good Manufacturing Practices (GMP) inspections; strengthening centralized systems for forecasting, procurement and distribution of quality medical products; and generating market intelligence.

As part of a multi-country project that ended in 2022, Nigeria participated in trainings led by the German Federal Institute for Drugs and Medical Devices (BfArM) to improve laboratory proficiency.

Team Europe funders

MAV+ actions in Nigeria are primarily funded by the European Union, Bulgaria, France, and Spain. Germany funds activities in Nigeria as part of multi-country projects. Additional co-financing and parallel funding from more Team Europe Member States is expected in 2025.

Partners

Partners on national projects include the Government of Nigeria, NIPRD (National Institute for Pharmaceutical Research and Development) and Emzor Pharmaceutical Industries Ltd. The National Agency for Food and Drug Administration and Control (NAFDAC) is involved in multi-country projects.

Additional Team Europe and international stakeholders

Stakeholders for national projects include EIB, Expertise France and UNICEF. Stakeholders for multi-country projects include German Federal Institute for Drugs and Medical Devices (BfArM), Institute for Pharmaceutical and Applied Analytics (InphA), UNIDO and WHO.